Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

I will discuss the use of genomics and data science in drug discovery at GSK, and particularly in the selection and validation of drug targets. I’ll highlight the interplay between experimental science and informatics, and will discuss recently published work highlighting the value of genetic information in selecting drug targets/indications. Motivated by this, I will also include a sketch of work ongoing and planned in this area at GSK, particularly with respect to the potential to integrate electronic health record and genomics information. I will also describe work at Open Targets  (, including both experimental and informatics aspects. I will focus on the key concepts and avoid technical detail, both regarding genomics and data science.